Everolimus, an mTOR (mammalian target of rapamycin) inhibitor, is one of the treatment options for HR-positive advanced/recurrent breast cancer, but it is known for its high incidence of DILD (3–33%), however its prognosis is relatively good [24–27]. The gene discussed is MTOR; the disease is breast carcinoma.